Sun Pharma’s $11.75 bn Organon deal may overpay for a declining women's‑health business
Sun Pharma’s $11.75 bn all‑cash purchase of Organon makes it a top‑three player in women’s health and a major biosimilar contender, but the deal hinges on a segment that is already falling. Organon’s Q1 results showed a 19% drop in women’s‑health sales and a 28% plunge in its flagship contraceptive implant, raising doubts about the debt‑financed deal’s cash‑flow assumptions.